Clinical Trial Update: Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19 [Phase 4]

View source ↗

Summary

Phase 4 trial update for apixaban in prophylaxis of thromboembolic outcomes in COVID-19 was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombosis

Drugs mentioned

• Apixaban (apixaban)

Snippet

Sponsor: Brazilian Clinical Research Institute | Conditions: Covid19, Thrombosis | Phase 4 | Status: TERMINATED